New Treatment Options Are in Play for Relapsed/ Refractory DLBCL
Up to 40% of patients with diffuse large B-cell lymphoma are refractory to or relapse after first-line treatment.
Superagonists Pull IL-15 Into Focus in Oncology Care
Following in the footsteps of the cytokine interleukin-2, IL-15 affords investigators similar qualities as a target without the associated toxicities of its immunotherapeutic predecessor.
Unmasking NETs Requires a Multifaceted Approach to Care
Eric Liu, MD, FACS, reviews treatment options, pitfalls of diagnoses, and
the importance of involving specialists and advocates early in neuroendocrine tumors.
Tackling the Adverse Effects of Immunotherapy
Igor Puzanov, MD, MSCI, FACP, discusses the adverse effects associated with immunotherapy and how to manage them.
Data-Driven Health Economics Research Can Improve Clinical, Economic Outcomes
Data-driven health economics and outcomes research offers clinicians effective methods for improving quality of life and outcomes for patients and optimizing economic benefits for the practice.
Genomic Testing Challenges Persist
Although molecular biomarkers are becoming increasingly relevant in cancer care, community oncologists confront a plethora of challenges in translating research findings into practice.
Nivolumab Plus Chemotherapy Moves Into Neoadjuvant Setting in NSCLC
Mark Awad, MD, PhD, discusses how the approval of nivolumab opens the door for the new regimen to become a backbone for future treatment strategies.
Second-Line Axi-Cel Offers a “Practice-Changing” Indication for LBCL
Lori A. Leslie, MD, reviews how the approval of axicabtagene ciloleucel may impact or enhance current practice patterns for adult patients with large B-cell lymphoma.
We Must Improve Communication With the Public
Maurie Markman, MD, discusses the need for oncologists to improve communication with the public and patients.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.